Urinary metabolomic profiling to identify potential biomarkers for the diagnosis of behcet’s disease by gas chromatography/time-of-flight- mass spectrometry

Joong Kyong Ahn, Jungyeon Kim, Jiwon Hwang, Juhwan Song, Kyoung Heon Kim, Hoon Suk Cha

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Diagnosing Behcet’s disease (BD) is challenging because of the lack of a diagnostic biomarker. The purposes of this study were to investigate distinctive metabolic changes in urine samples of BD patients and to identify urinary metabolic biomarkers for diagnosis of BD using gas chromatography/time-of-flighta-mass spectrometry (GC/TOF-MS). Metabolomic profiling of urine samples from 44 BD patients and 41 healthy controls (HC) were assessed using GC/TOF-MS, in conjunction with multivariate statistical analysis. A total of 110 urinary metabolites were identified. The urine metabolite profiles obtained from GC/TOF-MS analysis could distinguish BD patients from the HC group in the discovery set. The parameter values of the orthogonal partial least squared-discrimination analysis (OPLS-DA) model were R2X of 0.231, R2Y of 0.804, and Q2 of 0.598. A biomarker panel composed of guanine, pyrrole-2-carboxylate, 3-hydroxypyridine, mannose, L-citrulline, galactonate, isothreonate, sedoheptuloses, hypoxanthine, and gluconic acid lactone were selected and adequately validated as putative biomarkers of BD (sensitivity 96.7%, specificity 93.3%, area under the curve 0.974). OPLS-DA showed clear discrimination of BD and HC groups by a biomarker panel of ten metabolites in the independent set (accuracy 88%). We demonstrated characteristic urinary metabolic profiles and potential urinary metabolite biomarkers that have clinical value in the diagnosis of BD using GC/TOF-MS.

Original languageEnglish
Article number2309
JournalInternational Journal of Molecular Sciences
Volume18
Issue number11
DOIs
Publication statusPublished - 2017 Nov 2

Fingerprint

Metabolomics
Behcet Syndrome
biomarkers
Biomarkers
gas chromatography
Gas chromatography
Gas Chromatography
Mass spectrometry
Mass Spectrometry
mass spectroscopy
metabolites
Metabolites
urine
discrimination
Urine
multivariate statistical analysis
Citrulline
Control Groups
Hypoxanthine
Metabolome

Keywords

  • Behcet’s disease
  • Biomarker
  • Diagnosis
  • Gas chromatography-mass spectrometry
  • Metabolomics
  • Urine

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Urinary metabolomic profiling to identify potential biomarkers for the diagnosis of behcet’s disease by gas chromatography/time-of-flight- mass spectrometry. / Ahn, Joong Kyong; Kim, Jungyeon; Hwang, Jiwon; Song, Juhwan; Kim, Kyoung Heon; Cha, Hoon Suk.

In: International Journal of Molecular Sciences, Vol. 18, No. 11, 2309, 02.11.2017.

Research output: Contribution to journalArticle

@article{32f22200646d40e1a914234c8fc4cdc5,
title = "Urinary metabolomic profiling to identify potential biomarkers for the diagnosis of behcet’s disease by gas chromatography/time-of-flight- mass spectrometry",
abstract = "Diagnosing Behcet’s disease (BD) is challenging because of the lack of a diagnostic biomarker. The purposes of this study were to investigate distinctive metabolic changes in urine samples of BD patients and to identify urinary metabolic biomarkers for diagnosis of BD using gas chromatography/time-of-flighta-mass spectrometry (GC/TOF-MS). Metabolomic profiling of urine samples from 44 BD patients and 41 healthy controls (HC) were assessed using GC/TOF-MS, in conjunction with multivariate statistical analysis. A total of 110 urinary metabolites were identified. The urine metabolite profiles obtained from GC/TOF-MS analysis could distinguish BD patients from the HC group in the discovery set. The parameter values of the orthogonal partial least squared-discrimination analysis (OPLS-DA) model were R2X of 0.231, R2Y of 0.804, and Q2 of 0.598. A biomarker panel composed of guanine, pyrrole-2-carboxylate, 3-hydroxypyridine, mannose, L-citrulline, galactonate, isothreonate, sedoheptuloses, hypoxanthine, and gluconic acid lactone were selected and adequately validated as putative biomarkers of BD (sensitivity 96.7{\%}, specificity 93.3{\%}, area under the curve 0.974). OPLS-DA showed clear discrimination of BD and HC groups by a biomarker panel of ten metabolites in the independent set (accuracy 88{\%}). We demonstrated characteristic urinary metabolic profiles and potential urinary metabolite biomarkers that have clinical value in the diagnosis of BD using GC/TOF-MS.",
keywords = "Behcet’s disease, Biomarker, Diagnosis, Gas chromatography-mass spectrometry, Metabolomics, Urine",
author = "Ahn, {Joong Kyong} and Jungyeon Kim and Jiwon Hwang and Juhwan Song and Kim, {Kyoung Heon} and Cha, {Hoon Suk}",
year = "2017",
month = "11",
day = "2",
doi = "10.3390/ijms18112309",
language = "English",
volume = "18",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Urinary metabolomic profiling to identify potential biomarkers for the diagnosis of behcet’s disease by gas chromatography/time-of-flight- mass spectrometry

AU - Ahn, Joong Kyong

AU - Kim, Jungyeon

AU - Hwang, Jiwon

AU - Song, Juhwan

AU - Kim, Kyoung Heon

AU - Cha, Hoon Suk

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Diagnosing Behcet’s disease (BD) is challenging because of the lack of a diagnostic biomarker. The purposes of this study were to investigate distinctive metabolic changes in urine samples of BD patients and to identify urinary metabolic biomarkers for diagnosis of BD using gas chromatography/time-of-flighta-mass spectrometry (GC/TOF-MS). Metabolomic profiling of urine samples from 44 BD patients and 41 healthy controls (HC) were assessed using GC/TOF-MS, in conjunction with multivariate statistical analysis. A total of 110 urinary metabolites were identified. The urine metabolite profiles obtained from GC/TOF-MS analysis could distinguish BD patients from the HC group in the discovery set. The parameter values of the orthogonal partial least squared-discrimination analysis (OPLS-DA) model were R2X of 0.231, R2Y of 0.804, and Q2 of 0.598. A biomarker panel composed of guanine, pyrrole-2-carboxylate, 3-hydroxypyridine, mannose, L-citrulline, galactonate, isothreonate, sedoheptuloses, hypoxanthine, and gluconic acid lactone were selected and adequately validated as putative biomarkers of BD (sensitivity 96.7%, specificity 93.3%, area under the curve 0.974). OPLS-DA showed clear discrimination of BD and HC groups by a biomarker panel of ten metabolites in the independent set (accuracy 88%). We demonstrated characteristic urinary metabolic profiles and potential urinary metabolite biomarkers that have clinical value in the diagnosis of BD using GC/TOF-MS.

AB - Diagnosing Behcet’s disease (BD) is challenging because of the lack of a diagnostic biomarker. The purposes of this study were to investigate distinctive metabolic changes in urine samples of BD patients and to identify urinary metabolic biomarkers for diagnosis of BD using gas chromatography/time-of-flighta-mass spectrometry (GC/TOF-MS). Metabolomic profiling of urine samples from 44 BD patients and 41 healthy controls (HC) were assessed using GC/TOF-MS, in conjunction with multivariate statistical analysis. A total of 110 urinary metabolites were identified. The urine metabolite profiles obtained from GC/TOF-MS analysis could distinguish BD patients from the HC group in the discovery set. The parameter values of the orthogonal partial least squared-discrimination analysis (OPLS-DA) model were R2X of 0.231, R2Y of 0.804, and Q2 of 0.598. A biomarker panel composed of guanine, pyrrole-2-carboxylate, 3-hydroxypyridine, mannose, L-citrulline, galactonate, isothreonate, sedoheptuloses, hypoxanthine, and gluconic acid lactone were selected and adequately validated as putative biomarkers of BD (sensitivity 96.7%, specificity 93.3%, area under the curve 0.974). OPLS-DA showed clear discrimination of BD and HC groups by a biomarker panel of ten metabolites in the independent set (accuracy 88%). We demonstrated characteristic urinary metabolic profiles and potential urinary metabolite biomarkers that have clinical value in the diagnosis of BD using GC/TOF-MS.

KW - Behcet’s disease

KW - Biomarker

KW - Diagnosis

KW - Gas chromatography-mass spectrometry

KW - Metabolomics

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=85033609730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033609730&partnerID=8YFLogxK

U2 - 10.3390/ijms18112309

DO - 10.3390/ijms18112309

M3 - Article

C2 - 29099052

AN - SCOPUS:85033609730

VL - 18

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 11

M1 - 2309

ER -